Contract research organisations (CROs) are slashing clinical trial
times by an average of 30 per cent and the outsourcing trend is
showing no signs of slowing, as the pharma industry continues to
face rising pressure to reduce time-to-market...
Global drug development spending will top $105bn (€81.5bn) by 2010
and 40 per cent of this business is expected to be dished out in
outsourcing contracts - with contract research organisations (CROs)
Pharma firms may soon have the chance to use US prisoners in
clinical drug trials after a new report by a panel of medical
advisers at the Institute of Medicine recommended government laws
against the practice be loosened.
The use of eClinical software in clinical trials is gaining in
popularity with pharmaceutical, biotechnology and contract research
organizations (CROs), as seen by the recent financial results of
two major industry providers.
Covalent Group has signed a $1.7m (€1.3m) contract with a new,
undisclosed pharma firm to carry out a Phase II trial on a new drug
for atherosclerosis - a disease affecting the arterial blood
vessels throughout the body.
As global contract research spending remains robust, business is
booming for Pharmaceutical Product Development (PPD) as the US firm
reported a surge in sales, profits and new business for its second
Researchers have published a new article launching a scathing
attack on the growing incidence of healthcare professionals being
paid exuberant 'finder's fees' whenever they recruit a patient onto
a clinical trial.
The Food and Drug Administration (FDA) will beef up its process for
disclosing the conflicts of interest of its advisory experts in a
bid to restore its reputation after a survey suggests its
scientists may be too closely tied with...
The Food and Drug Administration (FDA) has been left red-faced
after a survey recently released by the Union of Concerned
Scientists (UCS), found a "disturbing level of interference in the
A new report compiled in the wake of the drug trial scandal, which
left six men fighting for their lives, has re-iterated the call for
scientists to proceed with extreme caution when testing such drugs
in the future.